EGFR and lung adenocarcinoma: In the study by Kasahar et al. [17], the pretreatment serum VEGF levels were measured in 95 patients with lung adenocarcinoma who received EGFR-TKI treatment, although patients presenting with a higher serum VEGF levels proved to have a poor tumor response, significantly shorter PFS and OS than patients with lower serum VEGF levels, these features did not independently determine OS in multivariate analysis.